Jung Corp · 66-66 · JAPAN
For Jung Corp · 66-66 · JAPAN, import alert is 66-66; import alert name is "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"; country is JAPAN; product is Doxorubicin HCL; product code is 56 H - S 24 Doxorubicin Hydrochloride (Antitumor), Active Pharm Ingred/Chems for Further Manuf; date published is 09/30/2009; address is 5-12 Nihonbashi , Tokyo Japan, JAPAN, verified against its source on 2026-09-16.
- Firm
- Jung Corp verified
- Import alert
- 66-66
- Import alert name
- "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"
- Country
- JAPAN verified
- Address
- 5-12 Nihonbashi , Tokyo Japan, JAPAN verified
- Date published
- 09/30/2009 verified
- Product code
- 56 H - S 24 Doxorubicin Hydrochloride (Antitumor), Active Pharm Ingred/Chems for Further Manuf verified
- Product
- Doxorubicin HCL verified
- FDA notes
- 11/2/2000 verified
What the source says
Jung Corp Date Published : 09/30/2009 5-12 Nihonbashi , Tokyo Japan, JAPAN 56 H - S 24 Doxorubicin Hydrochloride (Antitumor), Active Pharm Ingred/Chems for Further Manuf Date Published: 03/29/2019 Desc: Doxorubicin HCL Notes: 11/2/2000
— accessdata.fda.gov, retrieved 2026-09-15
Source
- accessdata.fda.govhttps://www.accessdata.fda.gov/cms_ia/importalert_202.html
This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.